Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
Phase of Trial: Phase I/II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Doravirine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 16 Nov 2017 Planned primary completion date changed from 1 Jun 2020 to 15 Jun 2019.